

History of Changes for Study: NCT00637377

VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2).

[Latest version \(submitted November 28, 2014\) on ClinicalTrials.gov](#)

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side comparison format applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently selected.
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in **red**.
- Study additions are displayed in **green**.

Study Record Versions

Version	A	B	Submitted Date	Changes
1	<input checked="" type="radio"/>	<input checked="" type="radio"/>	March 17, 2008	None (earliest Version on record)
2	<input type="radio"/>	<input type="radio"/>	April 24, 2008	Recruitment Status , Contacts/Locations, Study Status and Oversight
3	<input type="radio"/>	<input type="radio"/>	June 19, 2008	Contacts/Locations and Study Status

<https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop>

12/29/2020

History of Changes for Study: NCT00637377

Version	A	B	Submitted Date	Changes
4	<input type="radio"/>	<input type="radio"/>	August 4, 2008	Contacts/Locations, Study Status and Eligibility
5	<input type="radio"/>	<input type="radio"/>	September 30, 2008	Contacts/Locations, Study Status, Sponsor/Collaborators, Eligibility and Study Identification
6	<input type="radio"/>	<input type="radio"/>	October 2, 2008	Contacts/Locations, Study Status and Study Identification
7	<input type="radio"/>	<input type="radio"/>	November 4, 2008	Contacts/Locations, Study Status, Sponsor/Collaborators and Study Identification
8	<input type="radio"/>	<input type="radio"/>	December 1, 2008	Study Status and Contacts/Locations
9	<input type="radio"/>	<input type="radio"/>	January 5, 2009	Contacts/Locations and Study Status
10	<input type="radio"/>	<input type="radio"/>	February 5, 2009	Contacts/Locations and Study Status
11	<input type="radio"/>	<input type="radio"/>	March 5, 2009	Contacts/Locations, Study Status, Eligibility and Sponsor/Collaborators
12	<input type="radio"/>	<input type="radio"/>	April 2, 2009	Contacts/Locations, Study Status and Eligibility
13	<input type="radio"/>	<input type="radio"/>	May 4, 2009	Study Status
14	<input type="radio"/>	<input type="radio"/>	June 4, 2009	Contacts/Locations, Study Status and Eligibility
15	<input type="radio"/>	<input type="radio"/>	July 3, 2009	Contacts/Locations, Study Status and Eligibility
16	<input type="radio"/>	<input type="radio"/>	September 1, 2009	Contacts/Locations, Study Status and Eligibility
17	<input type="radio"/>	<input type="radio"/>	September 23, 2009	Recruitment Status, Contacts/Locations and Study Status
18	<input type="radio"/>	<input type="radio"/>	November 19, 2009	Study Status
19	<input type="radio"/>	<input type="radio"/>	February 19, 2010	Contacts/Locations, Study Status, Arms and Interventions, Study Design and Study Identification
20	<input type="radio"/>	<input type="radio"/>	July 9, 2010	Contacts/Locations and Study Status
21	<input type="radio"/>	<input type="radio"/>	October 6, 2010	Study Status

<https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop>

12/29/2020

History of Changes for Study: NCT00637377

Version	A	B	Submitted Date	Changes
22	<input type="radio"/>	<input type="radio"/>	November 30, 2010	Contacts/Locations, Study Status and Study Design
23	<input type="radio"/>	<input type="radio"/>	February 21, 2011	Study Status
24	<input type="radio"/>	<input type="radio"/>	May 23, 2011	Study Status, Contacts/Locations, Sponsor/Collaborators and Study Identification
25	<input type="radio"/>	<input type="radio"/>	June 6, 2011	Contacts/Locations, Arms and Interventions, Study Status, Study Identification, Outcome Measures, Sponsor/Collaborators
26	<input type="radio"/>	<input type="radio"/>	December 16, 2011	Recruitment Status, Study Status, Outcome Measures, Arms and Interventions, Study Identification, Outcome Measures, References, Contacts/Locations, Eligibility and Study Description
27	<input type="radio"/>	<input type="radio"/>	February 27, 2012	Study Status
28	<input type="radio"/>	<input type="radio"/>	March 12, 2013	Reported Adverse Events, Contacts/Locations, Study Status and References
29	<input type="radio"/>	<input type="radio"/>	April 25, 2014	Sponsor/Collaborators, Study Status, Baseline Characteristics and References
30	<input type="radio"/>	<input type="radio"/>	November 28, 2014	Study Status and References

Compare

Comparison Format: Merged
 Side-by-Side

[Scroll up to access the controls](#)

Study NCT00637377

Submitted Date: March 17, 2008 (v1)

Study Identification

Unique Protocol ID: 91689

Brief Title: VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW 2).

Official Title: A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety and Tolerability of VEGF Trap-Eye in Patients with Wet AMD

<https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop>

12/29/2020

History of Changes for Study: NCT00637377

Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Macular Degeneration (AMD).

Secondary IDs: EurdaCT No.: 2007-000583-25
311523
VIEW 2

Study Status

Record Verification: March 2008

Overall Status: Not yet recruiting

Study Start: March 2008

Primary Completion:

Study Completion: September 2011 [Anticipated]

First Submitted: March 12, 2008

First Submitted that Met QC Criteria: March 17, 2008

Met QC Criteria:

First Posted: March 18, 2008 [Estimate]

Last Update Submitted that Met QC Criteria: March 17, 2008

Met QC Criteria:

Last Update Posted: March 18, 2008 [Estimate]

Sponsor/Collaborators

Sponsor: Bayer

Responsible Party:

Collaborators: Regeneron Pharmaceuticals

Oversight

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

<https://clinicaltrials.gov/ct2/history/NCT00637377?A=1&B=1&C=merged#StudyPageTop>

Data Monitoring: Yes

Study Description

Brief Summary: This study is a phase III, double-masked, randomized, study of the efficacy and safety of ranibizumab (Lucentis) compared with bevacizumab (Avastin) in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

Detailed Description:

Conditions

Conditions: Macular Degeneration

Keywords: Eye diseases

Vision Impairment and Blindness

Eyes and Vision

Seniors

Neovascular Age-Related Macular Degeneration (AMD)

Retinal Disease

Study Design

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: Phase 3

Interventional Study Model: Parallel Assignment

Number of Arms: 4

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Allocation: Randomized

Enrollment: 1200 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
------	------------------------

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.